Trial Profile
A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs AB 2004 (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions
- Sponsors Axial Therapeutics
- 14 Feb 2022 According to an Axial Biotherapeutics media release, status changed from active, no longer recruiting to completed.
- 14 Feb 2022 According to an Axial Biotherapeutics media release, Robert L. Hendren, D.O., professor, psychiatry, Weill Institute for Neurosciences at the University of California, San Francisco, School of Medicine, is the principal investigator for the AB-2004 Phase 2 trial
- 14 Feb 2022 According to an Axial Biotherapeutics media release, Nature Medicine Publishes Full Results from Axial Therapeutics Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)